



# Continuous Glucose Monitoring in the Self-management of Type 2 Diabetes: A Paradigm Shift

*Diabetes Care* 2016;39:e71–e73 | DOI: 10.2337/dc15-2836

Daniel J. Cox,<sup>1</sup> Ann G. Taylor,<sup>2</sup>  
Matthew Moncrief,<sup>1</sup> Anne Diamond,<sup>1</sup>  
William S. Yancy Jr.,<sup>3</sup> Shefali Hegde,<sup>1</sup>  
and Anthony L. McCall<sup>4</sup>

Conventional lifestyle modification for type 2 diabetes involves 7% weight loss, avoidance of high-energy foods, and 150 min of weekly exercise (1). Although effective at preventing and treating diabetes, this approach is not appropriate for those who do not need or want to lose weight or who cannot maintain weight loss. An alternative may be to target postprandial glucose (PPG), the major contributor to HbA<sub>1c</sub> (2). The GEM (glycemic load, exercise, and monitoring blood glucose) lifestyle modification program focuses on diminishing PPG by selecting low-glycemic load foods to prevent PPG spikes, reducing PPG with postprandial exercise, and using systematic self-monitoring of blood glucose (SMBG). Systematic SMBG educates individuals about the impact of different foods and physical activities on PPG, activates them to take action when glucose is outside of desired limits, and motivates them to repeat choices that produce desired glucose levels. Therefore, GEM represents a paradigm shift from reducing insulin resistance through reducing fat to reducing PPG.

In a preliminary study, GEM effectively lowered HbA<sub>1c</sub> and promoted positive but not negative side effects (3). Despite the potential benefits of

systematic SMBG to educate, activate, and motivate positive choices, GEM subjects in the preliminary study (3) did not perform more SMBG than subjects undergoing routine care, despite receiving free SMBG supplies. We hypothesized that more robust glucose feedback might be advantageous.

Here reported is the feasibility and efficacy of replacing systematic SMBG with continuous glucose monitoring (CGM) to increase qualitative and quantitative feedback. By simply glancing at a CGM device, individuals can immediately access their current glucose level and its direction and rate of change.

Six recently diagnosed adults followed the GEM program and monitored glucose with CGM. Two dropped out because of psychiatric issues. Participants read five GEM manual chapters at home and then discussed their relevance to their daily routine during each of five group sessions (see preliminary study for details [3]). Participants were assessed at baseline and at 3-month follow-up. Subject demographics and results are shown in Table 1; the last column shows results from the GEM/SMBG preliminary study.

All subjects substantially lowered their HbA<sub>1c</sub>. Mean HbA<sub>1c</sub> fell from 7.8 to 6.7%,

which is a greater improvement than the reduction from 8.4 to 7.4% in the preliminary study. Participants also consumed fewer high-glycemic load foods, fewer grams of carbohydrate, and fewer calories without increasing fat intake.

Unlike those who used SMBG, subjects who monitored glucose with CGM during GEM reported eating more low-glycemic load foods in their daily routine and more frequently chose low-glycemic load foods in a behavioral challenge during pre/post assessments. Additionally, subjects who used CGM appeared to perform more SMBG and have fewer diabetes-associated problems (evaluated via Problem Areas in Diabetes [PAID] questionnaire) at follow-up.

This pilot study affirms the efficacy of GEM and further suggests that GEM intervention may be augmented with CGM to provide continuous and immediate feedback about the consequences of one's food and activity choices on glucose levels. These CGM benefits are consistent with the findings of Vigersky et al. (4). Studies that highlight the central role of glucose feedback in GEM, to educate, activate, and motivate individuals, contrast with research that found little benefit of nonsystematic use of SMBG by individuals managing

<sup>1</sup>Center for Behavioral Medicine Research, University of Virginia School of Medicine, Charlottesville, VA

<sup>2</sup>University of Virginia School of Nursing, Charlottesville, VA

<sup>3</sup>Durham Veterans Affairs Medical Center, Duke University School of Medicine, Durham, NC

<sup>4</sup>Division of Endocrinology and Metabolism, University of Virginia School of Medicine, Charlottesville, VA

Corresponding author: Daniel J. Cox, djc4f@virginia.edu.

Received 30 December 2015 and accepted 15 February 2016.

Clinical trial reg. no. NCT02432391, clinicaltrials.gov.

© 2016 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.

**Table 1—Demographics and pre/post measurements of subjects in the CGM/GEM study and group means for the earlier SMBG/GEM study**

	Assessment	Subjects				Mean	SD	SMBG/GEM (group mean)
		GEM052	GEM053	GEM054	GEM055			
<b>Demographics</b>								
Age (years)		60	57	66	65	62.0	4.2	55.3
Sex		F	F	M	F			
BMI (kg/m <sup>2</sup> )		55.5	30.6	26	38.1	37.6	13.0	
Duration of type 2 diabetes (years)		4.5	2	1	3	2.6	1.5	2.1
Medication (0 = none, 1 = metformin, 2 = two medications)		2	1	1	1	1.3	0.5	1
<b>Metabolic control</b>								
HbA <sub>1c</sub> (%) (Labs_HbA <sub>1c</sub> )	Pre	8	8	7	8	7.8	0.5	8.4
	Post	6.3	7.2	6.1	7	6.7	0.5	7.4
<b>Self-regulatory behaviors</b>								
Knowledge (Qz total score)	Pre	17	10	18	13	14.5	3.7	15.5
	Post	15	18	20	22	18.8	3.0	16.9
High-glycemic load foods (Qx_HGL)	Pre	21	25	18	45	27.3	12.2	30.7
	Post	9	7	0	9	6.3	4.3	14.9
Low-glycemic load foods (Qx_LGL)	Pre	22	36	47	34	34.8	10.2	42.4
	Post	42	22	76	89	57.3	30.7	37.5
Behavioral challenge (1 = low, 0 = high)	Pre	0	0	1	0	0.25		0.41
	Post	1	1	1	1	1		0.54
Total carbohydrates (ASA24_CARB)	Pre	328	328	126	191	243.3	101.4	223.3
	Post	215	161	110	116	150.5	48.7	131.1
Total fiber (ASA24_FIBE)	Pre	43	15	20	18	24.0	12.8	19.9
	Post	17	11	26	12	16.5	6.9	15.9
Total fat (ASA24_TFAT)	Pre	122	192	64	142	130.0	52.9	93.6
	Post	119	108	89	54	92.5	28.5	77.7
Saturated fat (ASA24_SFAT)	Pre	30	63	15	41	37.3	20.2	28.9
	Post	37	46	36	29	37.0	7.0	23.9
Protein (ASA24_PROT)	Pre	87	129	119	161	124.0	30.5	88.8
	Post	122	111	127	29	97.3	46.0	83.3
Calories (ASA24_KCAL)	Pre	2,698	3,557	1,510	2,956	2,680.3	859.2	2,085
	Post	2,399	2,059	1,708	1,019	1,796.3	590.0	1,545
Pedometer (steps)	Pre	1.67	0	32	0	8.4	15.7	20.1
	Post	13	0	39	0	13.0	18.4	35.4
#SMBG (SMBG/day)	Pre	4	4	5	5	4.3	0.6	2.9
	Post	2	2	3	2	2.4	0.4	1.6
<b>Physical measurements</b>								
SBP (Stats_Sys)	Pre	123	128	139	149	134.8	11.6	124.4
	Post	119	138	146	129	133.0	11.6	128.4
DBP (Stats_Dia)	Pre	70	70	90	77	76.8	9.4	79.1
	Post	79	85	98	84	86.5	8.1	81.4
Weight (Stats_Wt)	Pre	347	180	182	214	230.8	79.1	221
	Post	315	173	169	202	214.8	68.4	213.2
<b>Blood tests</b>								
HDL (Labs_HDL)	Pre	40	69	44	53	51.5	12.9	38.8
	Post	44	75	45	48	53.0	14.8	41.8
LDL (Labs_LDL)	Pre	85	176	122	128	127.8	37.4	101.9
	Post	69	176	134	152	132.8	45.9	110
Triglycerides (Labs_Tri)	Pre	130	180	96	153	139.8	35.6	161.9
	Post	82	71	83	192	107.0	56.9	175
<b>Psychological measurements</b>								
PAID-5	Pre	13	0	2	11	6.5	6.5	7.9
	Post	2	0	0	11	3.3	5.3	5.8

See the preliminary study (3) for more details on SMBG/GEM study data. DBP, diastolic blood pressure; F, female; M, male; SBP, systolic blood pressure.

type 2 diabetes (5). The small sample size and two dropouts limit extrapolation of findings.

**Acknowledgments.** The authors thank Lawrence Fisher, Department of Family and Community

Medicine, University of California, San Francisco, for thoughtful review and critique of the manuscript.

**Funding.** Dexcom grant IIS-2014-047 provided G4 PLATINUM CGM sets, supplies, and partial financial support to conduct this project.

**Duality of Interest.** D.J.C. received a grant from Dexcom that provided G4 PLATINUM CGM sets, supplies, and partial financial support to A.D. for this project. D.J.C. has served as a consultant for Pfizer, Merck, and Sanofi. The University of Virginia received support for contract research from Eli Lilly and Sanofi conducted by A.L.M. No

other potential conflicts of interest relevant to this article were reported.

The sponsor was not involved in the design or conduct of the study or in the preparation of the manuscript.

**Author Contributions.** D.J.C. wrote the manuscript and researched data. A.G.T., W.S.Y., and A.L.M. contributed to the discussion and reviewed and edited the manuscript. M.M. analyzed and researched data. A.D. ran the subjects and reviewed and edited the manuscript. S.H. was responsible for securing psychological questionnaire data. D.J.C. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

## References

1. Inzucchi SE, Bergenstal RM, Buse JB, et al.; American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD). Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetes Care* 2012;35:1364–1379
2. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA<sub>1c</sub>. *Diabetes Care* 2003;26:881–885
3. Cox DJ, Taylor AG, Singh H, et al. Glycemic load, exercise, and monitoring blood glucose (GEM): a paradigm shift in the treatment of type 2 diabetes mellitus. *Diabetes Res Clin Pract* 2016;111:28–35
4. Vigersky RA, Fonda SJ, Chellappa M, Walker MS, Ehrhardt NM. Short- and long-term effects of real-time continuous glucose monitoring in patients with type 2 diabetes. *Diabetes Care* 2012;35:32–38
5. Farmer AJ, Perera R, Ward A, et al. Meta-analysis of individual patient data in randomised trials of self monitoring of blood glucose in people with non-insulin treated type 2 diabetes. *BMJ* 2012;344:e486